C-MER Medical Holdings Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Dennis Lam

Chief Executive Officer (CEO)

HK$6.0m

Compensación total

Porcentaje del salario del CEO	95.7%
Permanencia del CEO	no data
Participación del CEO	0.9%
Permanencia media de la dirección	sin datos
Promedio de permanencia en la Junta Directiva	5.5yrs

Actualizaciones recientes de la dirección

Shareholders Will Probably Hold Off On Increasing C-MER Eye Care Holdings Limited's (HKG:3309) CEO Compensation For The Time Being

May 21

Recent updates

Is C-MER Medical Holdings (HKG:3309) A Risky Investment?

Oct 18

Not Many Are Piling Into C-MER Medical Holdings Limited (HKG:3309) Stock Yet As It Plummets 27%

Sep 04

Shareholders Will Probably Hold Off On Increasing C-MER Eye Care Holdings Limited's (HKG:3309) CEO Compensation For The Time Being

May 21

C-MER Eye Care Holdings' (HKG:3309) Earnings May Just Be The Starting Point

Apr 29

C-MER Eye Care Holdings Limited's (HKG:3309) 26% Share Price Plunge Could Signal Some Risk

Feb 02

C-MER Eye Care Holdings (HKG:3309) Might Be Having Difficulty Using Its Capital Effectively

Jan 17

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Dennis Lam en comparación con los beneficios de C-MER Medical Holdings?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jun 30 2024	n/a	n/a	HK$63m
Mar 31 2024	n/a	n/a	HK$63m
Dec 31 2023	HK$6m	HK$6m	HK$62m
Sep 30 2023	n/a	n/a	HK$28m
Jun 30 2023	n/a	n/a	-HK$7m
Mar 31 2023	n/a	n/a	-HK$14m
Dec 31 2022	HK$6m	HK$6m	-HK$22m
Sep 30 2022	n/a	n/a	HK$545k
Jun 30 2022	n/a	n/a	HK$23m
Mar 31 2022	n/a	n/a	HK$22m
Dec 31 2021	HK$6m	HK$6m	HK$22m
Sep 30 2021	n/a	n/a	HK$25m
Jun 30 2021	n/a	n/a	HK$28m
Mar 31 2021	n/a	n/a	HK$11m
Dec 31 2020	HK$4m	HK$4m	-HK$6m
Sep 30 2020	n/a	n/a	-HK$10m
Jun 30 2020	n/a	n/a	-HK$13m
Mar 31 2020	n/a	n/a	HK$14m
Dec 31 2019	HK$1m	HK$1m	HK$41m
Sep 30 2019	n/a	n/a	HK$53m
Jun 30 2019	n/a	n/a	HK$64m
Mar 31 2019	n/a	n/a	HK$53m
Dec 31 2018	HK$1m	HK$1m	HK$43m
Sep 30 2018	n/a	n/a	HK$35m
Jun 30 2018	n/a	n/a	HK$27m
Mar 31 2018	n/a	n/a	HK$31m
Dec 31 2017	HK$4m	HK$3m	HK$40m

Compensación vs. Mercado: La compensación total de Dennis($USD774.23K) está por encima de la media de empresas de tamaño similar en el mercado Hong Kong ($USD398.33K).

Compensación vs. Ingresos: La compensación de Dennis ha sido consistente con los resultados de la empresa en el último año.

CEO

Dennis Lam (64 yo)

no data

Permanencia

HK$6,018,000

Compensación

Dr. Shun Chiu Lam, JP, also known as Dennis, serves as Chairman and Chief Executive Officer of C-MER Medical Holdings Limited (formerly known as C-MER Eye Care Holdings Limited). Dr. Lam is also a director...

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Shun Chiu Lam	Chairman & CEO	no data	HK$6.02m	0.94% HK$ 27.0m
Xiaoting Li	Executive Director	7.4yrs	HK$3.81m	sin datos
Yau Wing Lee	Head of Hong Kong Operation & Executive Director	7.4yrs	HK$240.00k	1.08% HK$ 30.8m
Chiu Cheung Ma	Independent Non-Executive Director	6.9yrs	HK$240.00k	sin datos
Pak-kuen Auyeung	Independent Vice Chairman of the Board	4yrs	HK$759.00k	0.024% HK$ 699.1k
Ke Yin	Independent Non-Executive Director	1.3yrs	HK$120.00k	sin datos
Shu Kwan Ip	Independent Non-Executive Director	4yrs	HK$240.00k	sin datos

5.5yrs

Permanencia media

64yo

Promedio de edad

Junta con experiencia: La junta directiva de 3309 se considera experimentada (5.5 años de antigüedad promedio).

C-MER Medical Holdings Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Chairman & CEO recently bought HK$776k worth of stock

Chairman & CEO recently bought HK$841k worth of stock

Shareholders Will Probably Hold Off On Increasing C-MER Eye Care Holdings Limited's (HKG:3309) CEO Compensation For The Time Being

C-MER Eye Care Holdings Limited, Annual General Meeting, May 28, 2024

C-MER Eye Care Holdings Limited Announces Board Changes, Effective July 3, 2023

Insufficient new directors

Recent updates

Is C-MER Medical Holdings (HKG:3309) A Risky Investment?

Investor sentiment improves as stock rises 32%

Chairman & CEO recently bought HK$776k worth of stock

Investor sentiment deteriorates as stock falls 18%

Not Many Are Piling Into C-MER Medical Holdings Limited (HKG:3309) Stock Yet As It Plummets 27%

First half 2024 earnings released: EPS: HK$0.025 (vs HK$0.024 in 1H 2023)

C-MER Medical Holdings Limited to Report First Half, 2024 Results on Aug 29, 2024

Chairman & CEO recently bought HK$841k worth of stock

Shareholders Will Probably Hold Off On Increasing C-MER Eye Care Holdings Limited's (HKG:3309) CEO Compensation For The Time Being

C-MER Eye Care Holdings' (HKG:3309) Earnings May Just Be The Starting Point

C-MER Eye Care Holdings Limited, Annual General Meeting, May 28, 2024

New major risk - Revenue and earnings growth

C-MER Eye Care Holdings Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

C-MER Eye Care Holdings Limited's (HKG:3309) 26% Share Price Plunge Could Signal Some Risk

C-MER Eye Care Holdings (HKG:3309) Might Be Having Difficulty Using Its Capital Effectively

Price target decreased by 12% to HK$4.50

First half 2023 earnings released: EPS: HK$0.024 (vs HK$0.012 in 1H 2022)

C-MER Eye Care Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2023

C-MER Eye Care Holdings Limited to Report First Half, 2023 Results on Aug 30, 2023

C-MER Eye Care Holdings Limited Announces Board Changes, Effective July 3, 2023

Insufficient new directors

Now 21% undervalued after recent price drop

Now 22% undervalued after recent price drop

A Look At The Intrinsic Value Of C-MER Eye Care Holdings Limited (HKG:3309)

Full year 2022 earnings released: HK$0.018 loss per share (vs HK$0.019 profit in FY 2021)

Now 22% undervalued

Capital Allocation Trends At C-MER Eye Care Holdings (HKG:3309) Aren't Ideal

Insufficient new directors

Chairman & CEO recently bought HK$1.9m worth of stock

Chairman & CEO recently bought HK$1.3m worth of stock

Insufficient new directors

Is C-MER Eye Care Holdings (HKG:3309) A Risky Investment?

First half 2022 earnings released: EPS: HK$0.012 (vs HK$0.012 in 1H 2021)

Insufficient new directors

C-MER Eye Care Holdings Limited to Report First Half, 2022 Results on Aug 30, 2022

C-MER Eye Care Holdings Limited, Annual General Meeting, May 24, 2022

Full year 2021 earnings released: EPS: HK$0.019 (vs HK$0.006 loss in FY 2020)

C-MER Eye Care Holdings Limited Recommends No Payment of Any Final Dividend for the Year Ended 31 December 2021

C-MER Eye Care Holdings Limited (SEHK:3309) entered into the Sale and Purchase agreements to acquire Champion Eye Centre Limited from Yeung, Hung, Pauline Chan, Ko, DN Chan,Yip, and the Estate of Cheung for HKD 56.02 million.

Executive Director exercised options to buy HK$1.7m worth of stock.

C-MER Eye Care Holdings Limited (SEHK:3309) entered into an Equity Transfer Agreement to acquire 7% stake in Shenzhen Aikangjian Group Co., Ltd. from Shenzhen Capital Group Co., Ltd. for CNY 45.5 million

First half 2021 earnings released: EPS HK$0.012 (vs HK$0.02 loss in 1H 2020)

C-MER Eye Care Holdings Limited Provides Unaudited Consolidated Earnings Guidance for the Six Months Ended June 30, 2021

Independent Non-Executive Director recently bought HK$1.6m worth of stock

C-MER Eye Care Holdings Limited Approves Final Dividend for the Year Ended 31 December 2020

Upcoming dividend of HK$0.02 per share

Full year 2020 earnings released: HK$0.006 loss per share (vs HK$0.04 profit in FY 2019)

Full year 2020 earnings released: HK$0.006 loss per share (vs HK$0.04 profit in FY 2019)

C-MER Eye Care Holdings Limited to Report Fiscal Year 2020 Results on Mar 31, 2021

New 90-day high: HK$6.89

C-MER Eye Care Holdings Limited (SEHK:3309) signed a Purchase Agreement to acquire 60% stake in CAD/CAM Restorative Dental Centre Limited from YIU Bun Ka for HK$12.9 million.

New 90-day high: HK$6.44

Update: C-MER Eye Care Holdings (HKG:3309) Stock Gained 25% In The Last Year

Independent Non-Executive Director recently bought HK$1.8m worth of stock

C-MER Eye Care Holdings Limited Announces Board Changes

New 90-day low: HK$5.58

Independent Non-Executive Director recently bought HK$208k worth of stock

New 90-day low: HK$5.86

First half earnings released

Independent Non-Executive Director recently bought HK$138k worth of stock

Independent Non-Executive Director recently bought HK$130k worth of stock

First half earnings released

C-MER Eye Care Holdings Limited to Report First Half, 2020 Results on Aug 28, 2020

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Miembros de la Junta

Permanencia media